I-MAK
INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE
Sofosbuvir
Sofosbuvir is a pipeline hepatitis C (HCV) drug that has been recommended for treatment by the US FDA and EMA. HCV is a significant public health issue for low- and middle-income countries, that are home to 90% of the 185 million people who are infected with HCV. Although HCV is curable, high drug prices make treatment inaccessible, leaving people at risk for liver cancer or liver failure.
I-MAK filed an opposition against Gilead/Pharmasset's patent applications because we believe that the technologies comprising these patent applications are known and therefore undeserving of a patent grant. We also believe that it is now time that People Living with HCV obtain affordable access to the drugs they need.
Legal Documents for Opposition to Sofosbuvir (India)
I-MAK's Pre-Grant Opposition To The Prodrug Application (Without Exhibits)
I-MAK's Pre-Grant Opposition To The Prodrug Application (With Exhibits)
Background Information
Pricing Information And Speculation
Treatment Action Group: HIV, HCV And TB Pipeline Report
Media Coverage
'Indian Health Activists Move To Prevent Gilead’s Drug Patent' - Financial Times
'Hepatitis C Drug: US Group Opposes Gilead’s Patent Request In India' - Hindu Business Line
'Gilead Attempt To Secure Patent On Hepatitis C Drug Opposed In India' - Times Of India
'US Group Seeks To Block Gilead Drug Patent In India' - Yahoo News
Except for publications commissioned or published by third parties all content on this site is licensed under a Creative Commons Attribution 3.0 License
No comments:
Post a Comment